

# INSPIREMD, INC.

## **FORM 8-K** (Current report filing)

Filed 05/26/20 for the Period Ending 05/26/20

Telephone	(888) 776-6804
CIK	0001433607
Symbol	NSPR
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 26, 2020

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-35731**

(Commission  
File Number)

**26-2123838**

(IRS Employer  
Identification No.)

**4 Menorat Hamaor St.  
Tel Aviv, Israel**

(Address of principal executive offices)

**6744832**

(Zip Code)

**(888) 776-6804**

(Registrant's telephone number, including area code)

N/A

(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

(Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

(Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

((Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

((Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>(Trading Symbol(s)</u>	<u>Name of exchange on which registered</u>
Common Stock, par value \$0.0001 per share	NSPR	NYSE American
Warrants, exercisable for one share of Common Stock	NSPR.WS	NYSE American
Series B Warrants, exercisable for one share of Common Stock	NSPR.WSB	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 7.01 Regulation FD Disclosure

Beginning on May 26, 2020, InspireMD, Inc. (the “Company”) will make presentations to potential institutional and other investors as part of a “road show,” during which the Company will provide an overview of its business. A copy of the presentation materials to be shown to potential institutional and other investors is furnished herewith as Exhibit 99.1.

The presentation materials contain certain projections of the Company’s anticipated results of operations, or assumptions or estimates as to future events or outcomes. It is intended to speak only as of the date of this Report and should not be construed as representing projections of the Company’s anticipated results of operations, or assumptions or estimates as to future events or outcomes, as of any subsequent date. By furnishing the projections and other information in the presentation materials, the Company is not undertaking, and the Company expressly disclaims, any obligation to furnish updated or revised projections of the Company’s projected results of operations, or assumptions or estimates as to future events or outcomes, to reflect any events or circumstances occurring or existing at any time after the date hereof (irrespective in any such case of whether the projections, assumptions or estimates set forth in the presentation materials, in light of events or circumstances occurring or existing at any time after the date hereof, shall have ceased to have a reasonable basis). Consequently, the projections of the Company’s anticipated results of operations, assumptions and estimates set forth in the presentation materials furnished hereby should not be regarded as a representation by the Company that the projected results of operations can or will be achieved, only that the Company has concluded in good faith that they may be achieved based on many assumptions. The Company’s regular annual and quarterly financial statements, and the accompanying discussions and analyses of its financial condition and results of operations, contained in the Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission after the date of this Report will contain disclosure regarding the Company’s actual results of operations for fiscal periods covered by the projections in the presentation materials. The Company’s actual results could, and likely will, vary significantly from the potential results projected in the presentation materials, as a result of, among other things, changes in operations, factors affecting the Company’s business and industry, and the degree and timing to which management is able to execute its currently proposed business plan.

Please refer to page 2 of Exhibit 99.1 for a cautionary note regarding certain forward-looking statements included therein and the risks and uncertainties related thereto.

This information is being furnished pursuant to Item 7.01 of this Report and the exhibit being furnished as Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference and regardless of any general incorporation language in such filing. This inclusion of such information in this Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Presentation of InspireMD, Inc., as furnished on May 26, 2020</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**InspireMD, Inc.**

Date: May 26, 2020

By: /s/ Craig Shore  
Name: Craig Shore  
Title: Chief Financial Officer

---

Filed Pursuant to Rule 433  
Issuer Free Writing Prospectus dated May 26, 2020  
Relating to Prospectus filed May, 26, 2020  
Registration Statement No. 333- 238247



This presentation highlights basic information about InspireMD, Inc. and the offering. InspireMD, Inc. has filed a registration statement on Form S-1 (Registration No. 333-238247) (including a prospectus) with the U.S. Securities and Exchange Commission (the "SEC") for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the prospectus in that registration statement (including, among other things, risk factors described therein) and other documents the issuer has filed with the SEC for more complete information about InspireMD, Inc. and this offering. You may get these documents for free (including the preliminary prospectus dated May 26, 2020, and subsequent amendments) by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). Alternatively, InspireMD, Inc. or any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, by calling (212) 624-2060 or emailing [investmentbanking@alliance.com](mailto:investmentbanking@alliance.com).

To review a filed copy of our current registration statement, click on the following link:

[https://www.sec.gov/Archives/edgar/data/1433607/000149315220009800/forms\\_1a.htm](https://www.sec.gov/Archives/edgar/data/1433607/000149315220009800/forms_1a.htm)



Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Registration Statement No. 333-238247

# Sustained Emboic Protection

This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of the company nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

**InspireMD**

<http://www.inspiremd.com/en/>

## Disclaimers

This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payors for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.


## ■ Offering Summary

Issuer	InspireMD Inc.
Exchange: Ticker	NYSE American: NSPR
Offering Size	Up to \$10 million
Over Allotment	15%
Offering Details	Common Stock and/or Prefunded Warrants
Use of Proceeds	We plan to use the net proceeds of this offering for research and development, sales and marketing, and working capital and other general corporate purposes.
Sole Book Runner	A.G.P. / Alliance Global Partners



## About InspireMD





**InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally invasive indications utilizing an integrated embolic protection stent platform.**




MicroNet™ is a proprietary platform comprised of thin, 20-micron polyethylene terephthalate mesh that is designed to trap and maintain plaque stability against the arterial wall for protected flow to eliminate events such as heart attack, stroke and death.

- The company develops, manufactures and commercializes a portfolio of embolic protection systems
- MicroNet™, a key differentiator of InspireMD's commercial products, is revolutionizing the field of vascular stenting
- Today, InspireMD is a global company traded in the NYSE under NSPR

## Our Leadership

<p><b>Marvin L. Slosman</b> President and CEO</p>	<p>Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commercialization and international market development in both public and privately held companies. He has had senior management roles in a variety of public and privately held companies.</p>	
<p><b>Craig Shore</b> CFO</p>	<p>Mr. Shore has over 25 years of experience in financial management in the United States, Europe and Israel. He has served in various senior financial and general management roles at General Electric, Dunn and Bradstreet, Pfizer Pharmaceuticals and Bristol Myers Squibb.</p>	
<p><b>Paul Stuka</b> Chairman</p>	<p>Mr. Stuka was named to the Board of Directors in August of 2011 and serves as Chairman of the Board of Directors. Mr. Stuka is a Managing Member of Osiris Partners and a 30-year investment industry veteran.</p>	
<p><b>Michael Berman</b> Director</p>	<p>Mr. Berman is a successful entrepreneur within the medical device industry. He joined Scimed in 1986, leading its marketing activities until its merger with Boston Scientific in 1995. From 1995-2000, he served as President of Boston Scientific/Scimed.</p>	
<p><b>Campbell Rogers, M.D.</b> Director</p>	<p>Dr. Rogers currently serves as the CMO of HeartFlow, Inc., a private cardiovascular diagnostics company based in California.</p>	
<p><b>Thomas Kester</b> Director</p>	<p>Mr. Kester is CFO of Kester Search Group, Inc., a private executive search firm specializing in sales force placement for medical, dental and diagnostic device companies. He spent 28 years at KPMG LLP.</p>	



Proprietary MicroNet™  
Technology

**Commercial Stage**

**Stroke Protection:**  
CGuard™ EPS      The CGuard™ Carotid Stent with Embolic Prevention System (EPS) is designed to improve patient safety through sustained embolic protection<sup>1,2</sup> using our MicroNet™ technology.

**Myocardium Protection:**  
MGuard™ EPS      The MGuard™ EPS, integrated with MicroNet™, is designed to trap and seal thrombus and ruptured plaque, preventing embolization and optimize flow.

**Developing Products**


**Carotid Treatment:**      CGuard™ EPS US  
CGuard™ AV Shunt / Trans Cervical CAS

**Peripheral Treatment:**      PGuard™ EPS US

**Neuro Treatment:**      NGuard™

References: 1. Musalek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet-covered stent safety and stroke prevention efficacy. Presentation at ESC Congress 2019, Paris, France, 31 August 2019 to 4 September 2019. 2. Witsgott C et al. J Endovasc Ther 2017;24(1):130-137.

# Endovascular Procedures: Landscape and InspireMD Potential



<sup>1</sup> Behavi J, Gerlach DJ, Su Y, et al. Comparison of clipping and coiling in elderly patients with unruptured cerebral aneurysms. *J Neurosurg*. 2017;126(2):212-218.

<sup>2</sup> Celler JD, Rajagopal AD, Brown PV, et al. Trends in Coronary Revascularization Procedures Among Medicare Beneficiaries Between 2005 and 2012. *Circulation*. 2015;131(11):967-974.

<sup>3</sup> Bock AM, Soudain AL, Moss J, et al. Variation in Abdominal Aortic Aneurysm Care: A Report From the International Consortium of Vascular Registre. *Circulation*. 2016;134(24):2248-2259.


<sup>4</sup> Bartz D, Hornbary D R, Gonzalez C P, Eschebmatt B J, Parker L, Ass V M, & Levin D C. Recent Trends in Endovascular and Surgical Treatment of Peripheral Arterial Disease in the Medicare Population. *Am J Roentgenol*. 2010;194(5):963-966.

<sup>5</sup> 2017 Masimo Research International Market Report

## Stroke is the Second Biggest Cause of Death Globally

An estimated 15 million people suffer from stroke annually<sup>1</sup>

- 6.2 million deaths<sup>2</sup>
- 5 million people left permanently disabled<sup>1</sup>
- \$34 billion associated with stroke management in the US alone<sup>3</sup>
- ~85% of all strokes are ischemic strokes, which result from a lack of blood flow to the brain<sup>4</sup>
- Carotid artery disease (CAD) is a major risk factor for stroke
- ~20% of all ischemic strokes are estimated to be caused by CAD (2.2-2.4 million)<sup>5</sup>



<sup>1</sup> <http://www.who.int/health-topics/stroke-cerebrovascular-diseases/index.html>  
<sup>2</sup> [https://www.heart.org/healthycare/learn/abouth/heartdisease/press/documents/downloadable/00m\\_506473.pdf](https://www.heart.org/healthycare/learn/abouth/heartdisease/press/documents/downloadable/00m_506473.pdf)  
<sup>3</sup> Center For Disease Control and Prevention – Stroke Facts – 2017

<sup>4</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762837/>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851017/>  
<sup>5</sup> <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

## THE PROBLEM: Risks with Existing Approaches to CAD

Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks

### Carotid Endarterectomy (CEA)

Surgical Approach

Risk of complications:

- Myocardial infarction risk<sup>1</sup> (heart attack)
- Cranial nerve injury risk<sup>2</sup> (vertigo, hearing loss, paralysis, etc)
- Esthetic concern



### Carotid Artery Stenting (CAS)

Conventional Approach (Bare Stent)

Risk of complications:

- Procedural and post-procedural increase minor stroke risk<sup>1</sup>



Bare stent deployment




Based on the CREST clinical trial data<sup>2</sup>, in which only conventional carotid stents were used vs. surgery

<sup>1</sup> CREST Trial. N Engl J Med 2010;363:11-23  
<sup>2</sup> Circulation. 2012;125:2256-2264

## THE PROBLEM: Risk of Embolism Following Conventional CAS


MRI reveals post-procedural cerebral embolization



Cano et al. Rev Bras Cardiol Invasiva 2013; 21(2): 159-64.

## OUR SOLUTION: Proprietary MicroNet™ Technology

New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches




Conventional Stent:

Bare or dual layer approach, with plaque protrusion risk



Image: Prof. Vahid Qajani

Vs.



New Covered Stent:

Stents are covered in MicroNet™



Image: Prof. Vahid Qajani

### MicroNet™: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection

- Ultrathin flexible mesh sleeve, designed to expand seamlessly during stent deployment
- Net captures and locks thrombus and plaque materials against the arterial wall
- Prevents thrombus or plaque fragments dispersing, avoids debris entering the bloodstream
- Acts as a mechanical barrier to prevent plaque protrusion



# Carotid Solution: Our Well Studied Mesh-Covered Technology

More than 1,500 patients in Clinical Publications and Studies




## Timeline Growth: From Alternative Stent to New Gold Standard

YEAR	STUDY	PUBLICATION HIGHLIGHTS	CGUARD™'S STANDING (known & anticipated)
2015	CARENET 300	Safety, feasibility & neuroprotection; Neuroprotection over other stents data	<input checked="" type="checkbox"/> CGuard™ evaluated as new approach to CAS
2016	PARADIGM 101 300	All comers population; Excellent clinical results	
2017	CASANA	Large surgical center; Excellent clinical results	
2017	WISSGOTT	Clinical & mechanical assessment; Mechanical advantages vs competitive stents	<input checked="" type="checkbox"/> CGuard™ demonstrates best performance in field
2017	IRON-GUARD 1	Real world multicentric 30d results; Excellent clinical results in multicentric	
2018	WISSGOTT 10MM	"One size fit all"; Safety & feasibility of a size fit all approach	
2019	IRON-GUARD 1	Real world multicentric 1y results; Excellent long-term results in multicentric	
2020	IRON-GUARD 2 *	Large real world multicentric	<input type="checkbox"/> CGuard™ demonstrates superiority to other stents
2020	SIBERIA *	Randomized Trial; CGuard neuroprotection vs conventional stents	
2021	POLISH VASCULAR REGISTRY *	Large real world multicentric	
2022	OCTOPUS *	OCT comparison CGuard™ vs CEA; to demonstrate CGuard™ superior procedural results than CEA	
2022	PARADIGM EXTEND *	Large long-term study for all comers; CGuard™ study of long-term results	
2022	OPTIMA *	IVUS assessment after CGuard™; intended to demonstrate plaque exclusion	<input type="checkbox"/> CGuard™ demonstrates superiority to surgery
2023	FLOW-GUARD *	Use of CGuard™ as flow diverter in very high-risk patients beyond carotids; Potential new CGuard™ indications	

\* Expected

## CGuard™ EPS Yields Superior Clinical Outcomes

When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior




1. BROWN, ABO J. *Transcatheter Intervention* 2018 Nov;20: 14-1540-1162.  
2. BROWN, ABO J. *USAC* 2020.  
3. *ESSENTIAL For / World Endovascular Reg*; 2017 Dec: 41-4201-862.  
4. *WESSGOTT // Endovasc Ther* 2019;08: 35-078-582.  
5. *WESSGOTT // J Endovasc Ther* 2017; 24:120-127.  
6. *PARAGRAM Endovasc, EuroIntervention* on 2018 Aug 05: 12:4650-70. Updated LINC 2020.  
7. *ESSENTIAL JACC Cardiovasc Interv* 2019 Aug 17: 9:1229-1234.  
8. *ESSENTIAL Page / J Am Coll Cardiol* July 2: 11-25.

- CGuard™ has a superior profile versus historical data on both conventional carotid stents and surgery
- CGuard™ is a next-generation stent supported by a strong and growing body of clinical data
- 7 completed clinical trials and 4 ongoing trials
- NO MAJOR STROKE with CGuard™ (Minor stroke in 17/1,507 pts in 7 studies (1.13%))

## A Billion Dollar Market Opportunity

Our MicroNet™-covered stents like CGuard™ could become the new gold standard



- 2.2M diagnosed with carotid artery disease (CAD)
- 2017: ~600,000 patients with high grade carotid stenosis (HGCS) required interventions for CAD
- At present, ~80% are surgically treated CEA
- At a price of \$1,650 per stent, the addressable market is estimated to be more than \$1 billion

2017 Health Research International Market Report  
CAS – Carotid Artery Stenting  
CEA – Carotid Endarterectomy

## ■ Commercial Footprint (Dark Blue)



- Active Selling in 39 Countries
- Over 90% of sales are through channel partners / distributors
- Short Term Expansion Brazil and France
- New countries development include Japan, S Korea and China
- IDE Approval progressing with FDA; targeting initiation of US trial in 2021 (subject to FDA approval)

■ Our Lead Product, CGuard™ - Advancing Rapidly

**31%**


growth of CGuard™  
portfolio in Q4 2019

**18,000**


Total protected stents  
sold to date with  
excellent clinical results

CGuard™ has potential to  
become the new standard-of-  
care for carotid indications

\*Achieved clinical milestones;  
neuroprotective vs other carotid  
artery stenting (SERBIA)




■ Positioned for Growth



# Our Advancement Roadmap / Milestones

## Key Value Drivers and Strategic Pathways





## ■ Our Robust Intellectual Property Portfolio

Proprietary platform technology supported by IP

Patent Rights	Issued	Allowed	Pending
USA	14	0	3
Rest of World	33	4	14

- InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products

# Our Business and Market Development


## Strategic Targets for Merger or Acquisition



## Silk Road- Comparison

- Ticker SILK
- \$120 Million IPO (\$20 per share) – April 2019
- Valuation at time of IPO – \$600 Million
- Current Stock Price - \$37.46
- Market Value today - \$1.3 Billion
- Revenue in 2019 - \$63.1 Million (United States Only)

Silk Road Stock Performance since IPO



## Capitalization Table

Capitalization Table ( May 13, 2020)	# of Shares	WAEP - \$	Face Value \$	Exercise Value \$	% of Fully Diluted
Common Shares Outstanding	4,338,910				46.60%
Series B Preferred	555,138		\$570,999		5.96%
Series C Preferred	94,428		\$167,971		1.01%
Warrants (\$1.80-\$2.25)	3,166,665	\$1.83		\$5,787,497	34.01%
Warrants (\$6.25-\$188)	846,283	\$15.44		N/A	9.09%
Warrants (\$200 and above)	3,649	\$5,567.23		N/A	0.04%
RSU's	182,381				1.96%
Options	60,929	\$1.10		\$67,022	0.65%
Unit Purchase Option	63,402	\$1.29		\$81,510	0.68%
<b>Fully Diltued Shares Outstanding</b>	<b>9,311,785</b>				<b>100%</b>

## Company Highlights

<b>CGuard™ EPS</b>	<p><b>Enabling a paradigm shift</b> (CAS) in the treatment of carotid artery disease and stroke prevention</p> <p><b>Breakthrough platform:</b> Highly differentiated, with strong support from leading clinicians</p> <p><b>MicroNet™ technology</b> that is elegantly simple, proprietary and easily leveraged to other medical devices</p>
<b>Benefits Demonstrated in Multiple Trials</b>	<p><b>Clinical evidence / data driven:</b> 7 clinical trials completed with &gt;1,500 patient procedures and 4 ongoing clinical trials</p> <p><b>Differentiation</b> versus conventional carotid stents and surgery with both short- and long-term results</p> <p><b>Outcomes based:</b> No device related major adverse events. No major strokes or deaths related to device.</p> <p><b>Sustainable results:</b> Long term benefit reported in all-comer population</p>
<b>Commercial Growth</b>	<p><b>Expanding existing footprint:</b> Deeper penetration within key markets (18,000 devices sold to date)</p> <p><b>Results:</b> 2019 CGuard™ EPS sales increased 31% Q4/Q4</p> <p><b>Commercial model development:</b> Evaluating opportunities to go direct in key markets</p>
<b>\$1B Global Market Opportunity</b>	<p><b>Expansion into OUS markets:</b> Near term: Brazil; strategic partners discussions in Japan and China</p> <p><b>United States:</b></p> <ul style="list-style-type: none"> <li>• IDE FDA submission for CGuard™ EPS July 2019</li> <li>• Critical step in commencing human trial in the USA</li> </ul>
<b>Capital Structure</b>	<p>Recapitalized the company to clean up the capital structure and prepare for growth</p> <p><b>Capital use</b> focused on commercial execution and pipeline</p>
<b>Pipeline and Strategic Opportunities</b>	<p><b>Leverage</b> MicroNet™ into other pipeline opportunities in other neurovascular and peripheral techniques and treatments</p> <p><b>Proactively</b> seek synergistic product opportunities</p> <p><b>Add</b> BD resources to effectively assess inbound queries and implement a more focused and proactive BD strategy.</p>

Thank you

InspireMD

<http://www.inspiremd.com/en/>

